{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T05:40:39Z","timestamp":1737006039349,"version":"3.33.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1007\/s00347-007-1525-x","type":"journal-article","created":{"date-parts":[[2007,5,7]],"date-time":"2007-05-07T07:05:16Z","timestamp":1178521516000},"page":"517-520","source":"Crossref","is-referenced-by-count":0,"title":["Steroide bei Sehnerverkrankungen?","Steroids for optic nerve diseases?"],"prefix":"10.1007","volume":"104","author":[{"given":"W.A.","family":"Lagr\u00e8ze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1525_CR1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.49.5.1404","volume":"49","author":"Optic","year":"1997","unstructured":"Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49: 1404\u20131413","journal-title":"Neurology"},{"key":"1525_CR2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"Auphan","year":"1995","unstructured":"Auphan N, DiDonato JA, Rosette C et al. (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286\u2013290","journal-title":"Science"},{"key":"1525_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326: 581\u2013588","journal-title":"N Engl J Med"},{"key":"1525_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2004.01.040","volume":"137","author":"Beck","year":"2004","unstructured":"Beck RW, Gal RL, Bhatti MT et al. (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137: 77\u201383","journal-title":"Am J Ophthalmol"},{"key":"1525_CR5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199005173222001","volume":"322","author":"Bracken","year":"1990","unstructured":"Bracken MB, Shepard MJ, Collins WF et al. (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322: 1405\u20131411","journal-title":"N Engl J Med"},{"key":"1525_CR6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jama.1997.03540440031029","volume":"277","author":"Bracken","year":"1997","unstructured":"Bracken MB, Shepard MJ, Holford TR et al. (1997) Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277: 1597\u20131604","journal-title":"JAMA"},{"key":"1525_CR7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M","volume":"41","author":"Buttgereit","year":"1998","unstructured":"Buttgereit F, Wehling M, Burmester GR (1998) A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 41: 761\u2013767","journal-title":"Arthritis Rheum"},{"key":"1525_CR8","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1523\/JNEUROSCI.23-18-06993.2003","volume":"23","author":"Diem","year":"2003","unstructured":"Diem R, Hobom M, Maier K et al. (2003) Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 23: 6993\u20137000","journal-title":"J Neurosci"},{"key":"1525_CR9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/archneur.57.4.546","volume":"57","author":"Elovaara","year":"2000","unstructured":"Elovaara I, Ukkonen M, Leppakynnas M et al. (2000) Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 57: 546\u2013551","journal-title":"Arch Neurol"},{"key":"1525_CR10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0031-6997(24)01468-6","volume":"52","author":"Falkenstein","year":"2000","unstructured":"Falkenstein E, Tillmann HC, Christ M et al. (2000) Multiple actions of steroid hormones\u2013a focus on rapid, nongenomic effects. Pharmacol Rev 52: 513\u2013556","journal-title":"Pharmacol Rev"},{"key":"1525_CR11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1474-4422(06)70573-7","volume":"5","author":"Frohman","year":"2006","unstructured":"Frohman E, Costello F, Zivadinov R et al. (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol 5: 853\u2013863","journal-title":"Lancet Neurol"},{"key":"1525_CR12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/archneur.59.5.774","volume":"59","author":"Gelati","year":"2002","unstructured":"Gelati M, Corsini E, De Rossi M et al. (2002) Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch Neurol 59: 774\u2013780","journal-title":"Arch Neurol"},{"key":"1525_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(01)00330-7","volume":"117","author":"Gold","year":"2001","unstructured":"Gold R, Buttgereit F, Toyka KV (2001) Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117: 1\u20138","journal-title":"J Neuroimmunol"},{"key":"1525_CR14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/bmj.1.6075.1495","volume":"1","author":"Gould","year":"1977","unstructured":"Gould ES, Bird AC, Leaver PK, McDonald WI (1977) Treatmenf of optic neuritis by retrobulbar injection of triamcinolone. Br Med J 1: 1495\u20131497","journal-title":"Br Med J"},{"key":"1525_CR15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/jnnp.74.8.1139","volume":"74","author":"Hickman","year":"2003","unstructured":"Hickman SJ, Kapoor R, Jones SJ et al. (2003) Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry 74: 1139\u20131141","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1525_CR16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s000110050222","volume":"46","author":"Joyce","year":"1997","unstructured":"Joyce DA, Steer JH, Abraham LJ (1997) Glucocorticoid modulation of human monocyte\/macrophage function: control of TNF-alpha secretion. Inflamm Res 46: 447\u2013451","journal-title":"Inflamm Res"},{"key":"1525_CR17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.50.1.230","volume":"50","author":"Kapoor","year":"1998","unstructured":"Kapoor R, Miller DH, Jones SJ et al. (1998) Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 50: 230\u2013237","journal-title":"Neurology"},{"key":"1525_CR18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"Kappos","year":"2006","unstructured":"Kappos L, Antel J, Comi G et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124\u20131140","journal-title":"N Engl J Med"},{"key":"1525_CR19","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0161-6420(99)00707-1","volume":"106","author":"Levin","year":"1999","unstructured":"Levin LA, Beck RW, Joseph MP et al. (1999) The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology 106: 1268\u20131277","journal-title":"Ophthalmology"},{"key":"1525_CR20","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","volume":"83","author":"Mangelsdorf","year":"1995","unstructured":"Mangelsdorf DJ, Thummel C, Beato M et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835\u2013839","journal-title":"Cell"},{"key":"1525_CR21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121\u2013127","journal-title":"Ann Neurol"},{"key":"1525_CR22","first-page":"1","volume":"22","author":"Ohlsson","year":"2004","unstructured":"Ohlsson M, Mattsson P, Svensson M (2004) A temporal study of axonal degeneration and glial scar formation following a standardized crush injury of the optic nerve in the adult rat. Restor Neurol Neurosci 22: 1\u201310","journal-title":"Restor Neurol Neurosci"},{"key":"1525_CR23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00041327-200403000-00003","volume":"24","author":"Ohlsson","year":"2004","unstructured":"Ohlsson M, Westerlund U, Langmoen IA, Svensson M (2004) Methylprednisolone treatment does not influence axonal regeneration or degeneration following optic nerve injury in the adult rat. J Neuroophthalmol 24: 11\u201318","journal-title":"J Neuroophthalmol"},{"key":"1525_CR24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201eMcDonald Criteria\u201c. Ann Neurol 58: 840\u2013846","journal-title":"Ann Neurol"},{"key":"1525_CR25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0891-0618(97)00031-8","volume":"13","author":"Reagan","year":"1997","unstructured":"Reagan LP, McEwen BS (1997) Controversies surrounding glucocorticoid-mediated cell death in the hippocampus. J Chem Neuroanat 13: 149\u2013167","journal-title":"J Chem Neuroanat"},{"key":"1525_CR26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs. N Engl J Med 353: 1711\u20131723","journal-title":"N Engl J Med"},{"key":"1525_CR27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(04)17188-2","volume":"364","author":"Roberts","year":"2004","unstructured":"Roberts I, Yates D, Sandercock P et al. (2004) Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 364: 1321\u20131328","journal-title":"Lancet"},{"key":"1525_CR28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/archpsyc.57.10.925","volume":"57","author":"Sapolsky","year":"2000","unstructured":"Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57: 925\u2013935","journal-title":"Arch Gen Psychiatry"},{"key":"1525_CR29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.270.5234.283","volume":"270","author":"Scheinman","year":"1995","unstructured":"Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283\u2013286","journal-title":"Science"},{"key":"1525_CR30","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/123.7.1431","volume":"123","author":"Schmidt","year":"2000","unstructured":"Schmidt J, Gold R, Schonrock L et al. (2000) T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123: 1431\u20131441","journal-title":"Brain"},{"key":"1525_CR31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","volume":"52","author":"Sellebjerg","year":"1999","unstructured":"Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52: 1479\u20131484","journal-title":"Neurology"},{"key":"1525_CR32","first-page":"181","volume":"20","author":"Sheng","year":"2004","unstructured":"Sheng Y, Zhu Y, Wu L (2004) Effect of high dosage of methylprednisolone on rat retinal ganglion cell apoptosis after optic nerve crush. Yan Ke Xue Bao 20: 181\u2013186","journal-title":"Yan Ke Xue Bao"},{"key":"1525_CR33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/jnnp.64.4.505","volume":"64","author":"Steel","year":"1998","unstructured":"Steel DH, Waldock A (1998) Measurement of the retinal nerve fibre layer with scanning laser polarimetry in patients with previous demyelinating optic neuritis. J Neurol Neurosurg Psychiatry 64: 505\u2013509","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1525_CR34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/01.wno.0000204646.94991.68","volume":"26","author":"Steinsapir","year":"2006","unstructured":"Steinsapir KD (2006) Treatment of traumatic optic neuropathy with high-dose corticosteroid. J Neuroophthalmol 26: 65\u201367","journal-title":"J Neuroophthalmol"},{"key":"1525_CR35","first-page":"157","volume":"17","author":"Steinsapir","year":"2000","unstructured":"Steinsapir KD, Goldberg RA, Sinha S, Hovda DA (2000) Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor Neurol Neurosci 17: 157\u2013163","journal-title":"Restor Neurol Neurosci"},{"key":"1525_CR36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278\u2013285","journal-title":"N Engl J Med"},{"key":"1525_CR37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1167\/iovs.02-0304","volume":"44","author":"Trautner","year":"2003","unstructured":"Trautner C, Haastert B, Richter B et al. (2003) Incidence of blindness in southern Germany due to glaucoma and degenerative conditions. Invest Ophthalmol Vis Sci 44: 1031\u20131034","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1525_CR38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01203696","volume":"91","author":"Trauzettel-Klosinski","year":"1995","unstructured":"Trauzettel-Klosinski S, Diener HC, Dietz K, Zrenner E (1995) The effect of oral prednisolone on visual evoked potential latencies in acute optic neuritis monitored in a prospective, randomized, controlled study. Doc Ophthalmol 91: 165\u2013179","journal-title":"Doc Ophthalmol"},{"key":"1525_CR39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ana.20575","volume":"58","author":"Trip","year":"2005","unstructured":"Trip SA, Schlottmann PG, Jones SJ et al. (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58: 383\u2013391","journal-title":"Ann Neurol"},{"key":"1525_CR40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/bjo.2006.092031","volume":"90","author":"Trip","year":"2006","unstructured":"Trip SA, Schlottmann PG, Jones SJ et al. (2006) Quantification of optic nerve head topography in optic neuritis: a pilot study. Br J Ophthalmol 90: 1128\u20131131","journal-title":"Br J Ophthalmol"},{"key":"1525_CR41","doi-asserted-by":"crossref","unstructured":"Vedula S, Brodney-Folse S, Gal R, Beck R (2007) Corticosteroids for treating optic neuritis. Cochrane database of systematic reviews. (Online): CD001430","DOI":"10.1002\/14651858.CD001430.pub2"},{"key":"1525_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0021-5155(98)00071-9","volume":"43","author":"Wakakura","year":"1999","unstructured":"Wakakura M, Mashimo K, Oono S et al. (1999) Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 43: 133\u2013138","journal-title":"Jpn J Ophthalmol"},{"key":"1525_CR43","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1210\/endo.138.9.5489","volume":"138","author":"Watters","year":"1997","unstructured":"Watters JJ, Campbell JS, Cunningham MJ et al. (1997) Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138: 4030\u20134033","journal-title":"Endocrinology"},{"key":"1525_CR44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/112067210201200410","volume":"12","author":"Yip","year":"2002","unstructured":"Yip CC, Chng NW, Au Eong KG et al. (2002) Low-dose intravenous methylprednisolone or conservative treatment in the management of traumatic optic neuropathy. Eur J Ophthalmol 12: 309\u2013314","journal-title":"Eur J Ophthalmol"},{"key":"1525_CR45","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/me.2002-0106","volume":"16","author":"Yudt","year":"2002","unstructured":"Yudt MR, Cidlowski JA (2002) The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol 16: 1719\u20131726","journal-title":"Mol Endocrinol"},{"key":"1525_CR46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0165-5728(00)00337-4","volume":"110","author":"Zipp","year":"2000","unstructured":"Zipp F, Wendling U, Beyer M et al. (2000) Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells. J Neuroimmunol 110: 214\u2013222","journal-title":"J Neuroimmunol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-007-1525-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-007-1525-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-007-1525-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T02:26:13Z","timestamp":1736994373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-007-1525-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s00347-007-1525-x","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"type":"print","value":"0941-293X"},{"type":"electronic","value":"1433-0423"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}